Sign in
Taking people in United StatesNo phase

Comparing weight-loss medicine with a diet and exercise program for heart and metabolic health

Compares GLP-1 medicines with a lifestyle program in adults with overweight or obesity.

Key facts

Who runs it
Texas Tech University
Where
Lubbock, United StatesSee the site
Trial code
Registry title
Tirzepatide Impact Assessment Study
Status
Recruiting
People taking part
27 people, planned
Started
2 Jan 2025
Expected to end
7 Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • GLP-1 Receptor Agonist Therapy
  • Structured Lifestyle Intervention
Record updated
31 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a higher body weight who are either starting semaglutide or tirzepatide for weight loss, or want to lose weight without weight-loss medication.

Age
18 years or older.
Sex
All sexes can join.
Disease stage
BMI of 27.5 kg/m2 or higher.
Earlier treatment
Medication group: starting semaglutide or tirzepatide for weight loss, prescribed by their own doctor. Lifestyle group: no GLP-1 receptor agonist or other weight-loss medication now, and none in the past 3 months.

Main reasons for not taking part

  • Pregnant or breastfeeding
  • Pacemaker or other internal medical device
  • Chronic kidney disease in the past 2 years
  • Active cancer or cancer treatment within the past 6 months
  • Type 1 diabetes, or insulin treatment for type 2 diabetes

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Age 18 years or older
  • BMI of 27.5 kg/m2 or higher
  • For GLP-1 RA arm: initiating semaglutide or tirzepatide for weight loss as prescribed by their own medical provider
  • For LS comparator arm: not currently taking a GLP-1 receptor agonist or other weight-loss medication, and no use of weight-loss medication within the past 3 months

Who cannot take part

  • For LS comparator arm only: initiating any weight-loss medication (including a GLP-1 receptor agonist) currently or within the past 3 months
  • Chronic kidney disease in the past 2 years
  • Active cancer or cancer treatment within the past 6 months
  • Current diagnosis of any major endocrine, inflammatory, cardiovascular, or neurological disorder/condition, including Addison's disease, autism, congestive heart failure, Crohn's disease, Cushing's syndrome, hyperparathyroidism, multiple sclerosis, neuromuscular disorders (Guillain-Barre syndrome or myasthenia gravis), stroke, thyroid gland disorders (hyperthyroidism or hypothyroidism), type 1 diabetes, and ulcerative colitis
  • Insulin therapy for type 2 diabetes
  • Pregnant
  • Breastfeeding
  • Wears a pacemaker or other internal medical device

Where in United States

  • Nutrition Metabolic Health Initiative (NMHI)Lubbock, United StatesContact: Shannon Dr. Galyean, PhDTaking people

About the trial

What the trial wants to find out

This study examines how two different weight-loss strategies affect heart and metabolic health, as well as changes at the molecular level in the body. One group includes adults who are starting a GLP-1 receptor agonist medication (i.e., semaglutide or tirzepatide) prescribed by their own doctor for weight loss. The other group includes adults who will participate in a structured lifestyle program combining a reduced-calorie diet with increased physical activity. Both groups complete assessments at the start of the study and again after three months.

Read full original descriptionShow less

At each visit, participants have their weight, body composition, blood pressure, and resting metabolic rate measured. A blood draw is collected to evaluate cholesterol, blood sugar, insulin, appetite hormones, and liver and kidney function markers, and to analyze gene activity (RNA sequencing) and metabolites, which are small molecules that reflect how the body is using energy and nutrients. Participants also complete online questionnaires about diet, disordered eating, stress, mental health, and quality of life. Those in the lifestyle group attend three individual nutrition and physical activity counseling sessions over the course of the study.

The main goals of the study are (1) to determine whether GLP-1 receptor agonist medication or lifestyle changes produce greater improvements in heart and metabolic health markers over three months; (2) to examine if GLP-1 receptor agonist medication or lifestyle changes produce greater improvement in disordered eating, stress, mental health, and quality of life; (3) to investigate if GLP-1 receptor agonist medication or lifestyle changes produce greater improvement in appetite-related hormones (i.e., ghrelin, GLP-1, insulin, leptin, and peptide YY); and (4) to explore whether the two approaches cause different changes in gene expression and metabolic profiles. This is a pilot study conducted at Texas Tech University's Nutrition and Metabolic Health Initiative clinic in Lubbock, Texas.

Who can participate: Adults aged 18 years and older with a BMI of 27.5 or higher who are either starting semaglutide or tirzepatide therapy for weight management or who are seeking weight management without the use of weight-loss medications.

Who cannot participate: Individuals who are pregnant or lactating, have a pacemaker or internal medical device, have certain serious medical conditions (such as active cancer, uncontrolled hypertension, or severe kidney disease), have type 1 diabetes, or use insulin for type 2 diabetes.

The 2 groups in the trial

  • GLP-1 Receptor Agonist (Semaglutide or Tirzepatide)Treatment being tested

    Individuals in this study arm will be prescribed semaglutide or tirzepatide for weight management by their primary medical provider. Individuals will be invited to enroll in the study if they are starting semaglutide or tirzepatide within 0-3 days of coming into the NMHI clinic for their baseline assessment.

    Treatment: GLP-1 Receptor Agonist Therapy

  • Lifestyle Comparator ArmExisting treatment, for comparison

    Participants receive a structured lifestyle intervention delivered by a nutritional sciences graduate student and developed by a Registered Dietitian. The intervention targets a 500 kcal daily deficit from measured total energy expenditure and 150 to 300 minutes of moderate-intensity physical activity per week. Three individual education sessions are provided at baseline, one month, and two months. Dietary adherence is monitored via MyFitnessPal or a food journal. The same physical assessments and biospecimen collection procedures as the GLP-1 RA arm are completed at baseline and three months.

    Treatment: Structured Lifestyle Intervention

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Tirzepatide Impact Assessment: Exploring Health and Wellness Outcomes
Plain-language title
Comparing weight-loss medicine with a diet and exercise program for heart and metabolic healthGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
31 July 2026